NASDAQ:TECH Bio-Techne - TECH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bio-Techne Co. Please log in to your account or sign up in order to add this asset to your watchlist. $71.62 -1.79 (-2.44%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$71.42▼$73.4350-Day Range$71.62▼$82.2952-Week Range$68.00▼$113.81Volume504,753 shsAverage Volume929,526 shsMarket Capitalization$11.26 billionP/E Ratio44.48Dividend Yield0.45%Price Target$104.36 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Bio-Techne MarketRank™ ForecastAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside45.7% Upside$104.36 Price TargetShort InterestHealthy1.64% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainability-1.41Upright™ Environmental ScoreNews Sentiment0.69Based on 10 Articles This WeekInsider TradingN/AProj. Earnings Growth21.71%From $1.75 to $2.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.17 out of 5 starsMedical Sector21st out of 1,002 stocksBiological Products, Except Diagnostic Industry4th out of 166 stocks 4.4 Analyst's Opinion Consensus RatingBio-Techne has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $104.36, Bio-Techne has a forecasted upside of 45.7% from its current price of $71.62.Amount of Analyst CoverageBio-Techne has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.64% of the outstanding shares of Bio-Techne have been sold short.Short Interest Ratio / Days to CoverBio-Techne has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bio-Techne has recently increased by 0.78%, indicating that investor sentiment is decreasing. Previous Next 1.7 Dividend Strength Dividend YieldBio-Techne has a dividend yield of 0.44%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthBio-Techne has only been increasing its dividend for 1 years.Dividend CoverageThe dividend payout ratio of Bio-Techne is 19.88%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Bio-Techne will have a dividend payout ratio of 15.02% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBio-Techne has received a 69.12% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antibodies", "Biochemical assay kits", and "Laboratory reagents" products. See details.Environmental SustainabilityThe Environmental Impact score for Bio-Techne is -1.41. Previous Next 3.2 News and Social Media Coverage News SentimentBio-Techne has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Bio-Techne this week, compared to 4 articles on an average week.Search Interest33 people have searched for TECH on MarketBeat in the last 30 days. This is an increase of 230% compared to the previous 30 days.MarketBeat Follows6 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bio-Techne insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.45% of the stock of Bio-Techne is held by insiders.Percentage Held by InstitutionsOnly 23.92% of the stock of Bio-Techne is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Bio-Techne are expected to grow by 21.71% in the coming year, from $1.75 to $2.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bio-Techne is 44.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.44.Price to Earnings Ratio vs. SectorThe P/E ratio of Bio-Techne is 44.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.77.Price to Earnings Growth RatioBio-Techne has a PEG Ratio of 2.30. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBio-Techne has a P/B Ratio of 6.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bio-Techne (NASDAQ:TECH) StockBio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. TRead More Receive TECH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter. Email Address TECH Stock News HeadlinesMarch 27, 2023 | americanbankingnews.comStockNews.com Lowers Bio-Techne (NASDAQ:TECH) to HoldMarch 21, 2023 | americanbankingnews.comBio-Techne Co. (NASDAQ:TECH) Receives $104.36 Average Price Target from BrokeragesMarch 29, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 1, 2023 | finance.yahoo.comBIO-TECHNE ANNOUNCES INVESTMENT IN WILSON WOLFFebruary 28, 2023 | finance.yahoo.comBIO-TECHNE TO PRESENT AT THE COWEN 43rd ANNUAL HEALTH CARE CONFERENCEFebruary 24, 2023 | finance.yahoo.comExoDx PROSTATE TEST GRANTED EXPANDED COVERAGE BY MEDICAREFebruary 22, 2023 | finance.yahoo.comBIO-TECHNE TO PRESENT AT THE CITI 2023 HEALTHCARE SERVICES, MEDTECH, TOOLS & HCIT CONFERENCEFebruary 14, 2023 | finance.yahoo.comBIO-TECHNE AND CELL SIGNALING TECHNOLOGY ANNOUNCE PARTNERSHIP TO VALIDATE SIMPLE WESTERN ANTIBODIESMarch 29, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...February 8, 2023 | marketwatch.comProstaglandin E2 Market Research Report 2023 by Product, Application, End-users, Region And Global Forecast to 2028February 8, 2023 | msn.comThursday Is Your Last Chance To Buy Bio-Techne Before The Dividend PayoutFebruary 6, 2023 | finance.yahoo.comBio-Techne Corporation (NASDAQ:TECH) Q2 2023 Earnings Call TranscriptFebruary 5, 2023 | finance.yahoo.comBio-Techne Second Quarter 2023 Earnings: Misses ExpectationsFebruary 3, 2023 | marketwatch.com: Bio-Techne stock price target cut to $103.75 from $415.00 at Stifel NicolausJanuary 31, 2023 | finance.yahoo.comBIO-TECHNE ANNOUNCES RETIREMENT, APPOINTMENT OF GENERAL COUNSELJanuary 26, 2023 | finance.yahoo.comBIO-TECHNE LAUNCHES THE MauriceFlex™ SYSTEM, ADDING cIEF FRACTIONATION CAPABILITY TO THE GOLD STANDARD MAURICE ASSAYSJanuary 17, 2023 | finance.yahoo.comBIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 2, 2023, TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTSJanuary 10, 2023 | finance.yahoo.comBIO-TECHNE LAUNCHES RNASCOPE PLUS ASSAY TO ADVANCE GENE THERAPY DEVELOPMENTJanuary 7, 2023 | finance.yahoo.comA Look At The Fair Value Of Bio-Techne Corporation (NASDAQ:TECH)January 2, 2023 | marketwatch.comLegal Cocaine Market Research Highlighting Global Opportunities 2023 | Growth Trends and Share Forecast to 2029December 22, 2022 | finance.yahoo.comDo You Think Bio-Techne Corporation (TECH) Has a Positive Long-Term Trend?December 21, 2022 | finance.yahoo.comBIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCEDecember 17, 2022 | finance.yahoo.comOur 7 Top Biotech Stock Picks for 2023December 7, 2022 | finance.yahoo.comBio-Techne's (NASDAQ:TECH) investors will be pleased with their impressive 160% return over the last five yearsDecember 5, 2022 | finance.yahoo.comBIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLSDecember 1, 2022 | finance.yahoo.comBio-Techne and Oxford Nanopore Technologies partner to bring innovative reproductive health and carrier screening solutions to the marketNovember 28, 2022 | finance.yahoo.comBIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCESee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TECH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter. Email Address TECH Company Calendar Last Earnings11/01/2021Ex-Dividend for 2/27 Dividend2/10/2023Dividend Payable2/27/2023Today3/29/2023Next Earnings (Estimated)5/03/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:TECH CUSIP87837710 CIK842023 Webwww.bio-techne.com Phone(612) 379-8854Fax612-656-4400Employees3,000Year Founded1981Price Target and Rating Average Stock Price Forecast$104.36 High Stock Price Forecast$120.00 Low Stock Price Forecast$88.00 Forecasted Upside/Downside+45.7%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$1.61 Trailing P/E Ratio44.48 Forward P/E Ratio40.93 P/E Growth2.3Net Income$272.05 million Net Margins23.38% Pretax Margin28.39% Return on Equity15.87% Return on Assets11.92% Debt Debt-to-Equity Ratio0.11 Current Ratio4.40 Quick Ratio3.15 Sales & Book Value Annual Sales$1.11 billion Price / Sales10.19 Cash Flow$2.44 per share Price / Cash Flow29.34 Book Value$10.84 per share Price / Book6.61Miscellaneous Outstanding Shares157,270,000Free Float150,276,000Market Cap$11.26 billion OptionableOptionable Beta1.24 Social Links Key ExecutivesCharles R. KummethPresident, Chief Executive Officer & DirectorJames T. HippelChief Financial OfficerShane BohnenSecretary , General Counsel & Senior VPBrenda S. EversonChief Human Resources Officer & Senior VPRobert M. GavinVice President-Corporate DevelopmentKey CompetitorsQiagenNYSE:QGENRepligenNASDAQ:RGENNeurocrine BiosciencesNASDAQ:NBIXExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALOView All CompetitorsInsiders & InstitutionsETF Managers Group LLCBought 4,997 shares on 3/23/2023Ownership: 0.004%Victory Capital Management Inc.Bought 58,511 shares on 3/10/2023Ownership: 0.050%Rockefeller Capital Management L.P.Bought 15,252 shares on 3/6/2023Ownership: 0.013%Voya Investment Management LLCBought 442,983 shares on 2/28/2023Ownership: 0.386%Cascade Investment Group Inc.Bought 4,000 shares on 2/27/2023Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions TECH Stock - Frequently Asked Questions Should I buy or sell Bio-Techne stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TECH shares. View TECH analyst ratings or view top-rated stocks. What is Bio-Techne's stock price forecast for 2023? 9 brokers have issued twelve-month price objectives for Bio-Techne's stock. Their TECH share price forecasts range from $88.00 to $120.00. On average, they predict the company's stock price to reach $104.36 in the next twelve months. This suggests a possible upside of 45.7% from the stock's current price. View analysts price targets for TECH or view top-rated stocks among Wall Street analysts. How have TECH shares performed in 2023? Bio-Techne's stock was trading at $82.88 at the beginning of 2023. Since then, TECH stock has decreased by 13.6% and is now trading at $71.62. View the best growth stocks for 2023 here. When is Bio-Techne's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our TECH earnings forecast. How were Bio-Techne's earnings last quarter? Bio-Techne Co. (NASDAQ:TECH) released its earnings results on Monday, November, 1st. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts' consensus estimates of $0.43 by $0.03. The biotechnology company had revenue of $257.72 million for the quarter, compared to analysts' expectations of $254.37 million. Bio-Techne had a trailing twelve-month return on equity of 15.87% and a net margin of 23.38%. During the same quarter last year, the company earned $0.29 earnings per share. How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne? Bio-Techne declared a quarterly dividend on Thursday, February 2nd. Shareholders of record on Monday, February 13th will be paid a dividend of $0.08 per share on Monday, February 27th. This represents a $0.32 annualized dividend and a yield of 0.45%. The ex-dividend date is Friday, February 10th. This is a positive change from the stock's previous quarterly dividend of $0.02. Read our dividend analysis for TECH. What ETFs hold Bio-Techne's stock? ETFs with the largest weight of Bio-Techne (NASDAQ:TECH) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Alger Mid Cap 40 ETF (FRTY), American Century Mid Cap Growth Impact (MID), VanEck Biotech ETF (BBH), BlackRock Future Innovators ETF (BFTR), Alger 35 ETF (ATFV) and Putnam BioRevolution ETF (SYNB). Is Bio-Techne a good dividend stock? Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.44%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 19.88%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 15.02% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for TECH. When did Bio-Techne's stock split? Shares of Bio-Techne split before market open on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were issued to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. What is Charles Kummeth's approval rating as Bio-Techne's CEO? 95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees. What other stocks do shareholders of Bio-Techne own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA). What is Bio-Techne's stock symbol? Bio-Techne trades on the NASDAQ under the ticker symbol "TECH." Who are Bio-Techne's major shareholders? Bio-Techne's stock is owned by a variety of institutional and retail investors. Top institutional investors include Select Equity Group L.P. (4.55%), Bamco Inc. NY (3.51%), Neuberger Berman Group LLC (2.63%), Geode Capital Management LLC (2.34%), Winslow Capital Management LLC (2.00%) and Morgan Stanley (1.90%). Insiders that own company stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse. View institutional ownership trends. How do I buy shares of Bio-Techne? Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bio-Techne's stock price today? One share of TECH stock can currently be purchased for approximately $71.62. How much money does Bio-Techne make? Bio-Techne (NASDAQ:TECH) has a market capitalization of $11.26 billion and generates $1.11 billion in revenue each year. The biotechnology company earns $272.05 million in net income (profit) each year or $1.61 on an earnings per share basis. How many employees does Bio-Techne have? The company employs 3,000 workers across the globe. Does Bio-Techne have any subsidiaries? The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.Read More How can I contact Bio-Techne? Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for the company is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400. This page (NASDAQ:TECH) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.